<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jacobson, Anne</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Paganelli, Franck</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Tailored Clopidogrel Dosing Reduces Adverse Events in Patients with Clopidogrel Resistance Undergoing PCI</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2009</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2009-01-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">17-18</style></pages><abstract><style  face="normal" font="default" size="100%">For patients who undergo nonemergent percutaneous coronary intervention (PCI), tailoring the loading dose of clopidogrel according to platelet reactivity reduced the rate of early stent thrombosis, according to findings from a new trial. Individualized dosing also reduced the incidence of major adverse cardiovascular events without increasing bleeding events.</style></abstract><number><style face="normal" font="default" size="100%">8</style></number><volume><style face="normal" font="default" size="100%">8</style></volume></record></records></xml>